Risk-benefit assessment of angiotensin II receptor antagonists.

@article{Shusterman2002RiskbenefitAO,
  title={Risk-benefit assessment of angiotensin II receptor antagonists.},
  author={Neil Shusterman},
  journal={Expert opinion on drug safety},
  year={2002},
  volume={1 2},
  pages={137-52}
}
Inhibiting the renin-angiotensin-aldosterone system through the use of angiotensin-converting enzyme (ACE) inhibitors has proven very useful in the treatment of hypertension, congestive heart failure (CHF) and progressive renal failure. More recently, agents that directly block the angiotensin II Type 1 (AT(1)) receptor--angiotensin II receptor antagonists (AIIRAs)--have been developed. These agents are thought to have a more specific mechanism of action since they do not affect other hormone… CONTINUE READING